Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 9/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.52 |
| ▸ | CCNC | P24863 | 3/20 | 0.51 |
| ▸ | CDK8 | P49336 | 3/20 | 0.51 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.51 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274497 | 0.91 | HTT (0.54) | HTTEGFRNR2F2CCNCCDK8 | |
| SCHEMBL4260015 | 0.89 | HTT (0.52) | HTTEGFRNR2F2CCNCCDK8 | |
| SCHEMBL4269556 | 0.88 | HTT (0.52) | HTTEGFRNR2F2CCNCCDK8 | |
| SCHEMBL4264200 | 0.86 | HTT (0.54) | HTTEGFRNR2F2CCNCCDK8 | |
| SCHEMBL4260827 | 0.85 | EGFR (0.62) | HTTEGFRNR2F2CCNCCDK8 | |
| SCHEMBL4266991 | 0.85 | HTT (0.53) | HTTEGFRNR2F2CCNCCDK8 | |
| SCHEMBL4264695 | 0.85 | HTT (0.53) | HTTEGFRNR2F2CCNCCDK8 | |
| SCHEMBL29350229 | 0.85 | NFKB1 (0.63) | HTTEGFRNR2F2CCNCCDK8 | |
| SCHEMBL157421 | 0.85 | NFKB1 (0.63) | HTTEGFRNR2F2CCNCCDK8 | |
| SCHEMBL13912334 | 0.83 | EGFR (0.76) | HTTEGFRNR2F2CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | LU ZHIMIN | 2009-03-26 | — | — | US | claimed |
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | LU ZHIMIN | 2009-03-26 | — | — | US | disclosed |
| CN-101269077-A | Use of NF-kB inhibitors for treating retroviral infections | ZHIMIN LU (CN) | 2008-09-24 | — | — | CN | disclosed |
| CN-100418532-C | NF-kB compound inhibitor for treating various diseases | ZHIMIN LU (CN) | 2008-09-17 | — | — | CN | disclosed |
| CN-101239056-A | Use of NF-kB inhibitors for treating various diseases | ZHIMIN LU (CN) | 2008-08-13 | — | — | CN | disclosed |
| CN-1709259-A | Use of NF-kB inhibitors in the treatment of various diseases | LU ZHIMIN (CN) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | RELA, NFKBIA, NFKB1 | HTT 3989/4885EGFR 4591/4885NR2F2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.